<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://articlefeeds.nasdaq.com/~d/styles/itemcontent.css"?><rss xmlns:a10="http://www.w3.org/2005/Atom" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
  <channel xmlns:nasdaq="http://nasdaq.com/reference/feeds/1.0/">
    <title>Latest Articles about TTHI</title>
    <description />
    <language>EN-US</language>
    <lastBuildDate>Sat, 25 May 2013 16:57:58 -0400</lastBuildDate>
    <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://articlefeeds.nasdaq.com/nasdaq/symbols?symbol=TTHI" /><feedburner:info uri="nasdaq/symbols" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><item xml:base="http://www.nasdaq.com/article/elan-starts-phase-ii-ad-study-analyst-blog-cm193889">
      <guid isPermaLink="false">193889</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GnFOmD4bIWE/elan-starts-phase-ii-ad-study-analyst-blog-cm193889</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Elan Starts Phase II AD Study - Analyst Blog</title>
      <description>Elan Corporation  (  ELN  ) recently initiated a phase II study on ELND005 (Study AG201) for the treatment of agitation/aggression in patients suffering from moderate-to-severe Alzheimer's&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/GnFOmD4bIWE" height="1" width="1"/&gt;</description>
      <pubDate>Wed, 28 Nov 2012 21:20:01 Z</pubDate>
      <a10:updated>2012-11-28T18:41:21Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>ELN</nasdaq:tickers>
      <nasdaq:tickers>LLY</nasdaq:tickers>
      <nasdaq:tickers>PFE</nasdaq:tickers>
      <nasdaq:tickers>RHHBY</nasdaq:tickers>
      <nasdaq:tickers>TTHI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/elan-starts-phase-ii-ad-study-analyst-blog-cm193889</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/elan-starts-phase-ii-elnd005-study-analyst-blog-cm170752">
      <guid isPermaLink="false">170752</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o5ZaV1Vevgk/elan-starts-phase-ii-elnd005-study-analyst-blog-cm170752</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Elan Starts Phase II ELND005 Study - Analyst Blog</title>
      <description>Elan Corporation  (  ELN  ) recently initiated a phase II placebo-controlled, safety and efficacy study with oral ELND005. ELND005 is being developed as an adjunctive maintenance treatment in&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/o5ZaV1Vevgk" height="1" width="1"/&gt;</description>
      <pubDate>Fri, 07 Sep 2012 00:15:01 Z</pubDate>
      <a10:updated>2012-09-06T21:36:36Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>BIIB</nasdaq:tickers>
      <nasdaq:tickers>ELN</nasdaq:tickers>
      <nasdaq:tickers>JNJ</nasdaq:tickers>
      <nasdaq:tickers>TTHI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/elan-starts-phase-ii-elnd005-study-analyst-blog-cm170752</feedburner:origLink></item>
    <item xml:base="http://www.nasdaq.com/article/elan-lonza-in-supply-deal-analyst-blog-cm106888">
      <guid isPermaLink="false">106888</guid>
      <link>http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/50gM31nyUgA/elan-lonza-in-supply-deal-analyst-blog-cm106888</link>
      <category>Investing</category>
      <category>Business</category>
      <category>Stocks</category>
      <title>Elan, Lonza in Supply Deal - Analyst Blog</title>
      <description>Elan Corporation   (   ELN   ) recently announced that it has entered into a manufacturing agreement with   Lonza Group AG   (    LZAGY   ). As per the agreement, Lonza will supply the active&lt;img src="http://feeds.feedburner.com/~r/nasdaq/symbols/~4/50gM31nyUgA" height="1" width="1"/&gt;</description>
      <pubDate>Tue, 06 Dec 2011 01:00:01 Z</pubDate>
      <a10:updated>2011-12-05T21:02:17Z</a10:updated>
      <author>Zacks Equity Research</author>
      <nasdaq:tickers>API</nasdaq:tickers>
      <nasdaq:tickers>ELN</nasdaq:tickers>
      <nasdaq:tickers>PML</nasdaq:tickers>
      <nasdaq:tickers>TTHI</nasdaq:tickers>
    <feedburner:origLink>http://www.nasdaq.com/article/elan-lonza-in-supply-deal-analyst-blog-cm106888</feedburner:origLink></item>
  </channel>
</rss>
